Risk of urinary adverse effects of bevacizumab therapy in patients with ovarian cancer: a systematic review and meta-analysis
This study demonstrated that the use of Bevacizumab in patients with ovarian cancer significantly increases the overall risk of urinary complications, particularly proteinuria. These findings could contribute to enhanced awareness, facilitating the early identification and management of these adverse effects.
Authors
- Ahmed Karama
- Faisal Ahmed (ORCID: https://orcid.org/0000-0003-0015-6008)
- Adham Alkhammar
- Mazen Karama
- Mohammed Qaid
- Farida Noman
Institutions
- Federal Government of Mexico (MX)
- University of Aden (YE)
- Ibb University (YE)
Publication Details
- Journal
- Archivio Italiano di Urologia e Andrologia
- Published
- 2025-12-24
- DOI
- https://doi.org/10.4081/aiua.2025.14659
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00